IDEAYA enters clinical collaboration with AstraZeneca for IDE849 + Imfinzi in SCLC

IDEAYA Biosciences, Inc.

Collaboration to evaluate IDE849 (DLL3 TOP1 ADC) plus AstraZeneca's Imfinzi in extensive-stage SCLC.
IDEAYA sponsors the combination study; AstraZeneca supplies Imfinzi.
IDE849 Phase 1 global trial ongoing in DLL3-upregulated solid tumors including SCLC, NECs, NETs, melanoma.
No financial terms of the collaboration disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.